A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.

Sponsor
Shanghai Chest Hospital
Study ID
NCT05005468
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab is given on the first day of each cycle, intravenous drip.
  • Famitinib — DRUG
    Famitinib is administered orally, once a day.

Study Details

This is a phase II, open-label, multi-cohort study, aiming to investigate safety and efficacy of Camrelizumab combined with famitinib for adjuvant treatment of stage II-IIIA non-small cell lung cancer with high-risk for relapse and no driver gene mutation.

Key Dates

Start date
Sep 30, 2021
Status verified
Aug 2021
Primary completion
Aug 31, 2023
Completion
Aug 31, 2024

Study Design

Enrollment
61 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab Combined With Famitinib
    Drug: Camrelizumab Drug: Famitinib
  • No Intervention: Observation
    Observation

Primary Outcome Measure

DFS [ Time Frame: 6-18 months ]

Central Contacts

Related Studies